Global Multiple Sclerosis Pipeline Review 2016 - Pipeline Review of 178 Companies & Drug Profiles - Research and Markets

DUBLIN--()--Research and Markets has announced the addition of the "Multiple Sclerosis - Pipeline Review, H1 2016" report to their offering.

Multiple Sclerosis pipeline therapeutics constitutes close to 323 molecules. Out of which approximately 279 molecules are developed by Companies and remaining by the Universities

Institutes.

Multiple Sclerosis - Pipeline Review, H1 2016, outlays comprehensive information on the therapeutics under development for Multiple Sclerosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.

Multiple Sclerosis Multiple sclerosis (MS) is a potentially debilitating disease in which body's immune system eats away at the protective sheath (myelin) that covers nerves. Damage to myelin causes interference in the communication between brain, spinal cord and other areas of body. Symptoms include numbness or weakness in one or more limbs, double vision or blurring of vision, tingling or pain in parts of body, fatigue and slurred speech.

The predisposing factors include age, gender, family history and certain infections. The molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 3, 12, 29, 31, 166, 36 and 2 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 1, 3, 38 and 2 molecules, respectively.

Furthermore, this report also reviews of key players involved in therapeutic development for Multiple Sclerosis and features dormant and discontinued projects.

Companies Mentioned

  • 4D Pharma Plc
  • 4SC AG
  • AB Science SA
  • AbbVie Inc.
  • Ablynx NV
  • Acorda Therapeutics, Inc.
  • Actelion Ltd
  • Addex Therapeutics Ltd
  • Adhaere Pharmaceuticals, Inc.
  • Aegis Therapeutics, LLC
  • Affectis Pharmaceuticals AG
  • AiCuris GmbH & Co. KG
  • Alkermes Plc
  • Alpha Cancer Technologies Inc.
  • Amarna Therapeutics B.V.
  • Anavex Life Sciences Corp.
  • Antisense Therapeutics Limited
  • Antitope Limited
  • Aphios Corporation
  • Apitope International NV
  • Arena Pharmaceuticals, Inc.
  • Argos Therapeutics, Inc.
  • Arrien Pharmaceuticals, LLC
  • Artielle ImmunoTherapeutics, Inc.
  • Astellas Pharma Inc.
  • Asterias Biotherapeutics, Inc.
  • Atara Biotherapeutics, Inc.
  • Athersys, Inc.
  • Axxam SpA
  • Baliopharm AG
  • Bio-Cancer Treatment International Limited
  • BioAegis Therapeutics, Inc.
  • BIOCAD
  • Biocon Limited
  • Biogen, Inc.

For more information visit http://www.researchandmarkets.com/research/2kt2xs/multiple

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Central Nervous System Drugs , Immune Disorders Drugs

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Central Nervous System Drugs , Immune Disorders Drugs